Sun Pharma gets USFDA nod for nasal spray

Sun Pharma has received approval from the US Food and Drug Administration (USFDA) for its generic Azelastine HCL nasal spray, which is therapeutically equivalent to Medpointe Pharm HLC's Astelin nasal spray, Sun Pharma said in a statement
The drug is indicated for the treatment of the symptoms of seasonal allergic rhinitis such as rhinorrhea, sneezing and nasal pruritus.
It is also used for treating symptoms of vasomotor rhinitis, such as rhinorrhea, nasal congestion and postnasal drip in adults.
According to the company estimates, Azelastine HCL nasal spray has annual sales of around $144 million in the US
http://www.business-standard.com/india/news/sun-pharma-gets-usfda-nod-for-nasal-spray/165790/on